EP0531901A2 - Kondensierte Pyrazolderivate mit Interleukin-1 und Tumor Necrosis Faktor Inhibitor Wirkung - Google Patents
Kondensierte Pyrazolderivate mit Interleukin-1 und Tumor Necrosis Faktor Inhibitor Wirkung Download PDFInfo
- Publication number
- EP0531901A2 EP0531901A2 EP92115154A EP92115154A EP0531901A2 EP 0531901 A2 EP0531901 A2 EP 0531901A2 EP 92115154 A EP92115154 A EP 92115154A EP 92115154 A EP92115154 A EP 92115154A EP 0531901 A2 EP0531901 A2 EP 0531901A2
- Authority
- EP
- European Patent Office
- Prior art keywords
- alkyl
- compound
- salt
- formula
- defined above
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
- 0 Cc(c(*)c1N2C)n[n]1C(C)=C(*)C2=O Chemical compound Cc(c(*)c1N2C)n[n]1C(C)=C(*)C2=O 0.000 description 4
- CFYWNDYYRPLZQO-XQRVVYSFSA-N CC/C=N\NC Chemical compound CC/C=N\NC CFYWNDYYRPLZQO-XQRVVYSFSA-N 0.000 description 2
- WKFKSGIWKOVQEB-UHFFFAOYSA-N Cc1c(N)[nH]nc1I Chemical compound Cc1c(N)[nH]nc1I WKFKSGIWKOVQEB-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Definitions
- This invention relates to new heterocyclic derivatives. More particularly, this invention relates to pyrazole derivatives and pharmaceutically acceptable salts thereof which have pharmacological activities, processes for preparation thereof, a pharmaceutical composition comprising the same and a use of the same.
- one object of this invention is to provide the new and useful pyrazole derivatives and pharmaceutically acceptable salts thereof which possess a strong inhibitory activity on the production of Interleukin-1 (IL-1) and a strong inhibitory activity on the production of tumor necrosis factor (TNF).
- IL-1 Interleukin-1
- TNF tumor necrosis factor
- Another object of this invention is to provide processes for preparation of the pyrazole derivatives and salts thereof.
- a further object of this invention is to provide a pharmaceutical composition comprising said pyrazole derivatives or a pharmaceutically acceptable salt thereof.
- Still further object of this invention is to provide a use of said pyrazole derivatives or a pharmaceutically acceptable salt thereof as a medicament for prophylactic and therapeutic treatment of IL-I and TNF mediated diseases such as chronic inflammatory diseases, specific autoimmune diseases, sepsis-induced organ injury, and the like in human being and animals.
- IL-I and TNF mediated diseases such as chronic inflammatory diseases, specific autoimmune diseases, sepsis-induced organ injury, and the like in human being and animals.
- the object compound (I) of the present invention can be prepared by the following processes. wherein R1, R2 and Y are each as defined above, R3 is a leaving group, X1 and X7 are each halogen, X3, X5 and X6 are each a leaving group, X11 is an acid residue, R7, R8, R9, R 12 a , R15, R16, R17, R18, R19, R20, R21, R22, R23, R24, R25, R26, R27 and R28 are each hydrogen or substituent, R10 is acyl, R11 is lower alkyl, R 12 b is lower alkyl, R 1 a is lower alkyl, R 1 b is lower alkylsulfinylaryl or lower alkylsulfonylaryl, M is alkali earth metal, X12, X13, X14, X15, X16 and X17 are each a leaving group, R13 is esterified carboxyethen
- the starting compounds or salts thereof can be prepared by the following Processes. wherein R1, R2, R 12 a , X3, X11, R15 and R16 are each as defined above, X4, R5, X8, X9 and X10 are each a leaving group, R6 is lower alkyl, and X2 is halogen.
- Suitable pharmaceutically acceptable salts of the object compound (I) are conventional non-toxic salts and may include e.g. a salt with a base or an acid addition salt such as a salt with an inorganic base, for example, an alkali metal salt (e.g. sodium salt, potassium salt, etc.), an alkaline earth metal salt (e.g. calcium salt, magnesium salt, etc.), an ammonium salt; a salt with an organic base, for example, an organic amine salt (e.g.
- triethylamine salt pyridine salt, picoline salt, ethanolamine salt, triethanolamine salt, dicyclohexylamine salt, N,N'-dibenzylethylenediamine salt, etc.
- an inorganic acid addition salt e.g. hydrochloride, hydrobromide, sulfate, phosphate, etc.
- an organic carboxylic or sulfonic acid addition salt e.g. formate, acetate, trifluoroacetate, maleate, tartrate, methanesulfonate, benzenesulfonate, toluenesulfonate, etc.
- a salt with a basic or acidic amino acid e.g. arginine, aspartic acid, glutamic acid, etc.
- lower is used to intend a group having 1 to 6, preferably 1 to 4, carbon atom(s), unless otherwise provided.
- Suitable "lower alkyl” and “lower alkyl moiety" in the terms “lower alkylthioaryl”, “lower alkylsulfinylaryl” and “lower alkylsulfonylaryl” may include straight or branched one such as methyl, ethyl, propyl, isopropyl, butyl, t-butyl, pentyl, hexyl, and the like, in which more preferable example may be C1-C4 alkyl.
- heterocyclic group means saturated or unsaturated, monocyclic or polycyclic heterocyclic group containing at least one hetero-atom such as an oxygen, sulfur, nitrogen atom and the like.
- especially preferable heterocyclic group may be heterocyclic group such as unsaturated 3 to 8-membered more preferably 5 or 6-membered heteromonocyclic group containing 1 to 4-nitrogen atom(s), for example, pyrrolyl, pyrrolinyl, imidazolyl, pyrazolyl, pyridyl and its N-oxide, dihydropyridyl, pyrimidinyl, pyrazinyl, pyridazinyl, triazolyl (e.g.
- Suitable "acyl” may include carbamoyl, aliphatic acyl group and acyl group containing an aromatic ring, which is referred to as aromatic acyl, or heterocyclic ring, which is referred to as heterocyclic acyl.
- acyl may be illustrated as follows :- Carbamoyl; Aliphatic acyl such as lower or higher alkanoyl (e.g. formyl, acetyl, propanoyl, butanoyl, 2-methylpropanoyl, pentanoyl, 2,2-dimethylpropanoyl, hexanoyl heptanoyl, octanoyl, nonanoyl, decanoyl, undecanoyl, dodecanoyl, tridecanoyl, tetradecanoyl, pentadecanoyl, hexadecanoyl, heptadecanoyl, octadecanoyl, nonadecanoyl, icosanoyl, etc.); lower or higher alkoxycarbonyl (e.g.
- Aromatic acyl such as aroyl (e.g. benzoyl, toluoyl, naphthoyl, etc.); ar(lower)alkanoyl [e.g.
- phenyl(lower)alkanoyl e.g. phenylacetyl, phenylpropanoyl, phenylbutanoyl, phenylisobutylyl, phenylpentanoyl, phenylhexanoyl, etc.
- naphtyl(lower)alkanoyl e.g. naphthylacetyl, naphthylpropanoyl, naphthylbutanoyl, etc.
- ar(lower)alkenoyl e.g. phenyl(lower)alkenoyl (e.g.
- phenoxycarbonyl, naphthyloxycarbonyl, etc. aryloxy(lower)alkanoyl (e.g. phenoxyacetyl, phenoxypropionyl, etc.); arylcarbamoyl (e.g. phenylcarbamoyl, etc.); arylthiocarbamoyl (e.g. phenylthiocarbamoyl, etc.); arylglyoxyloyl (e.g. phenylglyoxyloyl, naphthylglyoxyloyl, etc.); arenesulfonyl (e.g.
- Heterocyclic acyl such as heterocycliccarbonyl; heterocyclic(lower)alkanoyl (e.g. thienylacetyl, thienylpropanoyl, thienylbutanoyl, thienylpentanoyl, thienylhexanoyl, thiazolylacetyl, thiadiazolylacetyl, tetrazolylacetyl, etc.); heterocyclic(lower)alkenoyl (e.g.
- Suitable "aryl” and “aryl moiety” in the terms “lower alkylthioaryl”, “lower alkylsulfinylaryl” and “lower alkylsulfonylaryl” may include phenyl, naphthyl and the like, in which more preferable example may be phenyl.
- Suitable "substituent" in the term "aryl which may have suitable substituent(s)” may include lower alkyl (e.g., methyl, ethyl, propyl, isopropyl, butyl, isobutyl, tert-butyl, pentyl, neopentyl, tert-pentyl, hexyl, etc.), lower alkoxy (e.g., methoxy, ethoxy, propoxy, isopropoxy, isobutoxy, tert-butoxy, pentyloxy, neopentyloxy, tert-pentyloxy, hexyloxy, etc.), lower alkenyl (e.g., vinyl, 1-propenyl, allyl, 1-methylallyl, 1 or 2 or 3-butenyl, 1 or 2 or 3 or 4-pentenyl, 1 or 2 or 3 or 4 or 5-hexenyl, etc.), lower alkynyl (
- Suitable "substituent" in the term “heterocyclic group which may have suitable substituent(s)” may include lower alkyl (e.g., methyl, ethyl, propyl, isopropy, butyl, isobutyl, tert-butyl, pentyl, neopentyl, tert-pentyl, hexyl, etc.), lower alkoxy (e.g., methoxy, ethoxy, propoxy, isopropoxy, isobutoxy, tert-butoxy, pentyloxy, neopentyloxy, tert-pentyloxy, hexyloxy, etc.), lower alkenyl (e.g., vinyl, 1-propenyl, allyl, 1-methylallyl, 1 or 2 or 3-butenyl, 1 or 2 or 3 or 4-pentenyl, 1 or 2 or 3 or 4 or 5-hexenyl, etc.), lower alkyn
- Suitable "protected carboxy” and “protected carboxy” moiety in the term “protected carboxy(lower)alkyl” may include esterified carboxy and the like.
- An suitable examples of said ester moiety may be the ones such as lower alkyl ester (e.g., methyl ester, ethyl ester, propyl ester, isopropyl ester, butyl ester, isobutyl ester, t-butyl ester, pentyl ester, t-pentyl ester, hexyl ester, 1-cyclopropylethyl ester, etc.); lower alkenyl ester (e.g., vinyl ester, allyl ester, etc.); lower alkynyl ester (e.g., ethynyl ester, propynyl ester, etc.); lower alkoxyalkyl ester (e.g., methoxymethyl ester, ethoxymethyl
- 2-iodoethyl ester, 2,2,2-trichloroethyl ester, etc. lower alkanoyloxy(lower)alkyl ester (e.g., acetoxymethyl ester, propionyloxymethyl ester, butyryloxymethyl ester, valeryloxymethyl ester, pivaloyloxymethyl ester, hexanoyloxymethyl ester, 2-acetoxyethyl ester, 2-propionyloxyethyl ester, etc.); lower alkanesulfonyl(lower)alkyl ester (e.g.
- ar(lower)alkyl ester for example, phenyl(lower)alkyl ester which may have one or more suitable substituent(s) (e.g., benzyl ester, 4-methoxybenzyl ester, 4-nitrobenzyl ester, phenethyl ester, trityl ester, benzhydryl ester, bis(methoxyphenyl)methyl ester, 3,4-dimethoxybenzyl ester, 4-hydroxy-3,5-di-t-butylbenzyl ester, etc.); aryl ester which may have one or more suitable substituent(s) such as substituted or unsubstituted phenyl ester (e.g., phenyl ester, tolyl ester, t-butylphenyl ester, xylyl ester, mesityl ester, cumenyl ester, 4-chloroph
- ester moiety in the terms “esterified carboxyethenyl”, “esterified carboxyethyl” and “esterified carboxymethyl” may be the same as exemplified above.
- Suitable "protected amino” may include acylamino wherein acyl moiety can be referred to the ones as exemplified above, or the like.
- Suitable "protected hydroxy” and “protected hydroxy” moiety in the term “protected hydroxy(lower)alkyl” may include acyloxy wherein acyl moiety can be referred to the ones as exemplified above, or the like.
- Suitable “leaving group” may include lower alkoxy (e.g. methoxy, ethoxy, propoxy, isopropoxy, butoxy, isobutoxy, t-butoxy, pentoxy, etc.), aryloxy (e.g. phenoxy, naphthoxy, etc.), an acid residue or the like.
- Suitable “acid residue” may be halogen (e.g. chlorine, bromine, iodine, etc.), sulfonyloxy (e.g. methanesulfonyloxy, benzenesulfonyloxy, mesitylenesulfonyloxy, toluenesulfonyloxy, etc.) or the like.
- Suitable "halogen” may be the same as exemplified above.
- Suitable "alkali earth metal” may include magnesium, calcium, and the like.
- Suitable "substituent in the definition of R7, R8, R9, R 12 a , R15, R16, R17, R18, R19, R20, R21, R22, R23, R24, R25, R26, R27 and R28 may include lower alkyl (e.g., methyl, ethyl, propyl, isopropyl, butyl, isobutyl, tert-butyl, pentyl, neopentyl, tert-pentyl, hexyl, etc.), lower alkoxy (e.g., methoxy, ethoxy, propoxy, isopropoxy, isobutoxy, tert-butoxy, pentyloxy, neopentyloxy, tert-pentyloxy, hexyloxy, etc.), lower alkenyl (e.g., vinyl, 1-propenyl, allyl, 1-methylallyl, 1 or 2 or 3-
- Suitable "substituent” in the terms “propandial which may have suitable substituent(s)", “acrylaldehyde which may have suitable substituent(s)” and “esterified carboxyethenyl, esterified carboxyethyl or esterified carboxymethyl, each of which may have suitable substituent(s)” may include lower alkyl (e.g., methyl, ethyl, propyl, isopropyl, butyl, isobutyl, tert-butyl, pentyl, neopentyl, tert-pentyl, hexyl, etc.), lower alkoxy (e.g., methoxy, ethoxy, propoxy, isopropoxy, isobutoxy, tert-butoxy, pentyloxy, neopentyloxy, tert-pentyloxy, hexyloxy, etc.), lower alkenyl (e.g., vinyl, 1-prop
- Suitable "substituent” in the terms "bivalent radical selected from each of which may have suitable substituent(s)", “bivalent radical selected from each of which may have suitable substituent(s)", “bivalent radical selected from each of which may have suitable substituent(s)", “bivalent radical selected from each of which may have suitable substituent(s)", “bivalent radical selected from each of which may have suitable substituent(s)", “bivalent radical selected from each of which may have suitable substituent(s)”, “bivalent radical selected from each of which may have suitable substituent(s)”, “bivalent radical selected from each of which may have suitable substituent(s)", “bivalent radical selected from each of which may have suitable substituent(s), which may have suitable substituent(s)” and which may have suitable substituent(s)” may include lower alkyl (e.g., methyl, ethyl, propyl, isopropyl, butyl, isobutyl, tert-butyl, pent
- the compound (Ia) or a salt thereof can be prepared by reacting the compound (IIa) or a salt thereof with the compound (III) or a salt thereof.
- This reaction is usually carried out in a solvent such as alcohol (e.g., methanol, ethanol, etc.), benzene, N,N-dimethylformamide, tetrahydrofuran, methylene chloride, ethylene chloride, chloroform, diethyl ether or any other solvent which does not adversely affect the reaction.
- a solvent such as alcohol (e.g., methanol, ethanol, etc.), benzene, N,N-dimethylformamide, tetrahydrofuran, methylene chloride, ethylene chloride, chloroform, diethyl ether or any other solvent which does not adversely affect the reaction.
- the reaction temperature is not critical and the reaction is usually carried out under cooling to heating.
- the reaction is usually carried out in the presence of an acid including Lewis acid.
- Suitable acid may include an organic acid [e.g. formic acid, acetic acid, propionic acid, trichloroacetic acid, trifluoroacetic acid, etc.] and an inorganic acid [e.g. hydrochloric acid, hydrobromic acid, sulfuric acid, hydrogen chloride, hydrogen bromide, zinc halide (e.g. zinc chloride, zinc bromide, etc.), etc.] and the like.
- organic acid e.g. formic acid, acetic acid, propionic acid, trichloroacetic acid, trifluoroacetic acid, etc.
- an inorganic acid e.g. hydrochloric acid, hydrobromic acid, sulfuric acid, hydrogen chloride, hydrogen bromide, zinc halide (e.g. zinc chloride, zinc bromide, etc.), etc.
- the compound (Ic) or a salt thereof can be prepared by subjecting the compound (Ib) or a salt thereof to reduction reaction.
- Reduction is carried out in a conventional manner, including chemical reduction and catalytic reduction.
- Suitable reducing agents to be used in chemical reduction are hydrides (e.g. hydrogen iodide, hydrogen sulfide, lithium aluminum hydride, sodium borohydride, lithium borohydride, diborane, sodium cyanoborohydride, etc.) or a combination of a metal (e.g. tin, zinc, iron, etc.) or metallic compound (e.g. chromium chloride, chromium acetate, etc.) and an organic or inorganic acid (e.g. formic acid, acetic acid, propionic acid, trifluoroacetic acid, p-toluene-sulfonic acid, hydrochloric acid, hydrobromic acid, etc.).
- a metal e.g. tin, zinc, iron, etc.
- metallic compound e.g. chromium chloride, chromium acetate, etc.
- organic or inorganic acid e.g. formic acid, acetic acid, propionic acid
- Suitable catalysts to be used in catalytic reduction are conventional ones such as platinum catalysts (e.g. platinum plate, spongy platinum, platinum black, colloidal platinum, platinum oxide, platinum wire, etc.), palladium catalysts (e.g. spongy palladium, palladium black, palladium oxide, palladium on carbon, colloidal palladium, palladium on barium sulfate, palladium on barium carbonate, etc.), nickel catalysts (e.g. reduced nickel, nickel oxide, Raney nickel, etc.), cobalt catalysts (e.g. reduced cobalt, Raney cobalt, etc.), iron catalysts (e.g. reduced iron, Raney iron, etc.), copper catalysts (e.g. reduced copper, Raney copper, Ullman copper, etc) and the like.
- platinum catalysts e.g. platinum plate, spongy platinum, platinum black, colloidal platinum, platinum oxide, platinum wire, etc.
- palladium catalysts e.g. spongy pal
- the reaction is usually carried out in a solvent such as water, alcohol (e.g. methanol, ethanol, etc.), N,N-dimethylformamide, tetrahydrofuran, a mixture thereof or any other solvent which does not adversely affect the reaction.
- a solvent such as water, alcohol (e.g. methanol, ethanol, etc.), N,N-dimethylformamide, tetrahydrofuran, a mixture thereof or any other solvent which does not adversely affect the reaction.
- reaction temperature of this reaction is not critical and the reaction is usually carried out under cooling to heating.
- the compound (Id) or a salt thereof can be prepared by reacting the compound (II) or a salt thereof with the compound (IV) or a salt thereof.
- the reaction is usually carried out in a conventional solvent such as alcohols (e.g. methanol, ethanol, ethylene glycol, etc.), chloroform, ether, tetrahydrofuran, benzene or any other organic solvent which does not adversely influence the reaction.
- a conventional solvent such as alcohols (e.g. methanol, ethanol, ethylene glycol, etc.), chloroform, ether, tetrahydrofuran, benzene or any other organic solvent which does not adversely influence the reaction.
- the reaction temperature is not critical and the reaction is usually carried out under cooling to heating.
- the reaction may be also carried out in the presence of an inorganic or an organic base such as an alkali metal hydroxide, an alkali metal hydrogencarbonate, alkali metal carbonate, tri(lower)alkylamine, alkali metal hydride (e.g. sodium hydride, etc.), alkali metal (lower)alkoxide (e.g. sodium methoxide, sodium ethoxide, etc.), pyridine lutidine, picoline, dimethylaminopyridine, N-(lower)alkylmorpholine, N,N-di(lower)alkylbenzylamine, N,N-di(lower)alkylaniline or the like.
- an inorganic or an organic base such as an alkali metal hydroxide, an alkali metal hydrogencarbonate, alkali metal carbonate, tri(lower)alkylamine, alkali metal hydride (e.g. sodium hydride, etc.), alkali metal (lower)
- the compound (If) or a salt thereof can be prepared by subjecting the compound (Ie) or a salt thereof to reduction reaction.
- the compound (Ig) or a salt thereof can be prepared by reacting the compound (XIIIa) or a salt thereof with the compound (XIV).
- This reaction is usually carried out in a solvent such as water, alcohol (e.g., methanol, ethanol, etc.), benzene, N,N-dimethylformamide, tetrahydrofuran, toluene, methylenechloride, ethylene dichloride, chloroform, diethyl ether or any other solvent which does not adversely affect the reaction.
- a solvent such as water, alcohol (e.g., methanol, ethanol, etc.), benzene, N,N-dimethylformamide, tetrahydrofuran, toluene, methylenechloride, ethylene dichloride, chloroform, diethyl ether or any other solvent which does not adversely affect the reaction.
- the reaction temperature is not critical and the reaction is usually carried out under warming to heating.
- the compound (Ih) or a salt thereof can be prepared by reacting the compound (II) or a salt thereof with the compound (XV) or a salt thereof.
- This reaction is usually carried out in a solvent such as water, alcohol (e.g., methanol, ethanol, etc.), benzene, N,N-dimethylformamide, tetrahydrofuran, toluene, methylenechloride, ethylene dichloride, chloroform, diethyl ether or any other solvent which does not adversely affect the reaction.
- a solvent such as water, alcohol (e.g., methanol, ethanol, etc.), benzene, N,N-dimethylformamide, tetrahydrofuran, toluene, methylenechloride, ethylene dichloride, chloroform, diethyl ether or any other solvent which does not adversely affect the reaction.
- the reaction temperature is not critical and the reaction is usually carried out under warming to heating.
- the reaction is usually carried out in the presence of an inorganic or an organic base such as an alkali metal (e.g., sodium, potassium, etc.), an alkali metal hydroxide (e.g., sodium hydroxide, potassium hydroxide, etc.), an alkali metal hydrogencarbonate (e.g., sodium hydrogencarbonate, potassium hydrogencarbonate, etc.), alkali metal carbonate (e.g., sodium carbonate, potassium carbonate, etc.), tri(lower)alkylamine (e.g., trimethylamine, triethylamine, diisopropylethylamine, etc.), alkali metal hydride (e.g., sodium hydride, etc.), alkali metal (lower)alkoxide (e.g., sodium methoxide, sodium ethoxide, etc.), pyridine, lutidine,picoline, dimethylaminopyridine, N-(lower)alkylmorpholine, N,N-di(lower)
- the base and/or the starting compound When the base and/or the starting compound are in liquid, they can be also as a solvent.
- the compound (Ii) or a salt thereof can be prepared by reacting the compound (XVI) or a salt thereof with the compound (XVII) or a salt thereof.
- This reaction is usually carried out in a solvent such as water, alcohol (e.g, methanol, ethanol, etc.), benzene, N,N-dimethylformamide, tetrahydrofuran, toluene, methylenechloride, ethylene dichloride, chloroform, diethyl ether or any other solvent which does not adversely affect the reaction.
- a solvent such as water, alcohol (e.g, methanol, ethanol, etc.), benzene, N,N-dimethylformamide, tetrahydrofuran, toluene, methylenechloride, ethylene dichloride, chloroform, diethyl ether or any other solvent which does not adversely affect the reaction.
- the reaction temperature is not critical and the reaction is usually carried out under cooling to warming.
- the compound (Id) or a salt thereof can be prepared by subjecting the compound (XXVII) or a salt thereof to cyclization reaction.
- This reaction is usually carried out by a method using the catalyst such as an organic acid [e.g. formic acid, acetic acid, propionic acid, trichloroacetic acid, trifluoroacetic acid, etc.] and an inorganic acid [e.g. hydrochloric acid, hydrobromic acid, sulfuric acid, hydrogen chloride, hydrogen bromide, etc.] and the like.
- an organic acid e.g. formic acid, acetic acid, propionic acid, trichloroacetic acid, trifluoroacetic acid, etc.
- an inorganic acid e.g. hydrochloric acid, hydrobromic acid, sulfuric acid, hydrogen chloride, hydrogen bromide, etc.
- the acid and/or the starting compound When the acid and/or the starting compound are in liquid, they can be also as a solvent.
- This reaction is usually carried out in a solvent such as water, alcohol (e.g, methanol, ethanol, etc.), benzene, N,N-dimethylformamide, tetrahydrofuran, toluene, methylenechloride, ethylene dichloride, chloroform, diethyl ether or any other solvent which does not adversely affect the reaction.
- a solvent such as water, alcohol (e.g, methanol, ethanol, etc.), benzene, N,N-dimethylformamide, tetrahydrofuran, toluene, methylenechloride, ethylene dichloride, chloroform, diethyl ether or any other solvent which does not adversely affect the reaction.
- the reaction temperature is not critical and the reaction is usually carried out under warming to heating.
- the compound (Il) or a salt thereof can be prepared by reacting the compound (Ik) or a salt thereof with the compound (XIX) or a salt thereof.
- This reaction is usually carried out in a solvent such as benzene, N,N-dimethylformamide, tetrahydrofuran, toluene, methylenechloride, ethylene dichloride, chloroform, diethyl ether or any other solvent which does not adversely affect the reaction.
- a solvent such as benzene, N,N-dimethylformamide, tetrahydrofuran, toluene, methylenechloride, ethylene dichloride, chloroform, diethyl ether or any other solvent which does not adversely affect the reaction.
- the reaction temperature is not critical and the reaction is usually carried out under cooling to warming.
- the reaction is usually carried out in the presence of an inorganic or an organic base such as an alkali metal, an alkali metal hydroxide, an alkali metal hydrogencarbonate, alkali metal carbonate, tri(lower)alkylamine, alkali metal hydride (e.g. sodium hydride, etc.), alkali metal (lower)alkoxide (e.g. sodium methoxide, sodium ethoxide, etc.), pyridine, lutidine, picoline, dimethylaminopyridine, N-(lower)alkylmorpholine, N,N-di(lower)alkylbenzylamine, N,N-di(lower)alkylaniline or the like.
- an inorganic or an organic base such as an alkali metal, an alkali metal hydroxide, an alkali metal hydrogencarbonate, alkali metal carbonate, tri(lower)alkylamine, alkali metal hydride (e.g. sodium hydride
- the base and/or the starting compound When the base and/or the starting compound are in liquid, they can be also used as a solvent.
- the compound (In) or a salt thereof can be prepared by subjecting the compound (Im) or a salt thereof to oxidation reaction.
- Oxidation is carried out in a conventional manner, which is capable of oxidizing a sulfur atom to an oxidized sulfur atom
- suitable oxidizing reagent may be oxygen acid such as periodate (e.g. sodium periodate, potassium periodate, etc.), peroxy acid such as peroxybenzoic acid (e.g., peroxybenzoic acid, m-chloroperoxybenzoic acid, etc.), and the like.
- the reaction is usually carried out in a conventional solvent such as tetrahydrofuran, dioxane, dichloromethane, ethylene dichloride, chloroform, N,N-dimethylformamide, N,N-dimethylacetamide, or any other organic solvent which does not adversely affect the reaction.
- a conventional solvent such as tetrahydrofuran, dioxane, dichloromethane, ethylene dichloride, chloroform, N,N-dimethylformamide, N,N-dimethylacetamide, or any other organic solvent which does not adversely affect the reaction.
- the reaction temperature is not critical and the reaction is usually carried out under cooling to warming.
- the compound (Ip) or a salt thereof can be prepared by reacting the compound (Io) or a salt thereof with the compound (XX) or a salt thereof.
- This reaction is usually carried out in a solvent such as benzene, N,N-dimethylformamide, tetrahydrofuran, toluene, methylenechloride, ethylene dichloride, chloroform, diethyl ether or any other solvent which does not adversely affect the reaction.
- a solvent such as benzene, N,N-dimethylformamide, tetrahydrofuran, toluene, methylenechloride, ethylene dichloride, chloroform, diethyl ether or any other solvent which does not adversely affect the reaction.
- the reaction temperature is not critical and the reaction is usually carried out under cooling to warming.
- the compound (Iq) or a salt thereof can be prepared by reacting the compound (Ip) or a salt thereof with the compound (XXI) or a salt thereof.
- This reaction is usually carried out in a solvent such as benzene, N,N-dimethylformamide, tetrahydrofuran, toluene, methylenechloride, ethylene dichloride, chloroform, diethyl ether or any other solvent which does not adversely affect the reaction.
- a solvent such as benzene, N,N-dimethylformamide, tetrahydrofuran, toluene, methylenechloride, ethylene dichloride, chloroform, diethyl ether or any other solvent which does not adversely affect the reaction.
- the reaction temperature is not critical and the reaction is usually carried out under cooling to warming.
- the compound (Ir) or a salt thereof can be prepared by subjecting the compound (Iq) or a salt thereof to oxidation reaction.
- Oxidation is carried out in a conventional manner, which is capable of oxidizing N-acyl substituted dihydropyridine to pyridine, and suitable oxidizing reagent may be sulfur, oxygen, alkali metal alkoxide, (e.g., potassium t-butoxide, etc.), or the like.
- suitable oxidizing reagent may be sulfur, oxygen, alkali metal alkoxide, (e.g., potassium t-butoxide, etc.), or the like.
- the reaction is usually carried out in a conventional solvent such as water, alcohol (e.g., methanol, ethanol, isopropyl alcohol, t-butyl alcohol, etc.), tetrahydrofuran, dioxane, dichloromethane, chloroform, N,N-dimethylacetamide, N,N-dimethylformamide, decalin, tetralin or any other organic solvent which does not adversely affect the reaction.
- a conventional solvent such as water, alcohol (e.g., methanol, ethanol, isopropyl alcohol, t-butyl alcohol, etc.), tetrahydrofuran, dioxane, dichloromethane, chloroform, N,N-dimethylacetamide, N,N-dimethylformamide, decalin, tetralin or any other organic solvent which does not adversely affect the reaction.
- alcohol e.g., methanol, ethanol, isopropyl alcohol, t-but
- hydrophilic solvents may be used in a mixture with water.
- the reaction temperature is not critical and the reaction is usually carried out under warming to heating.
- the compound (It) or a salt thereof can be prepared by subjecting the compound (Ik) or its reactive derivative at the imino group or a salt thereof to acylation reaction.
- Suitable acylating agent to be used in the present acylation reaction may include the compound of the formula : R 12 c - OH (XXXVI (wherein R 12 c is acyl) or its reactive derivative or a salt thereof.
- Suitable reactive derivative at the imino group of the compound (Ik) may include a silyl derivative formed by the reaction of the compound (Ik) with a silyl compound such as N,O-bis(trimethylsilyl)acetamide, N-trimethylsilylacetamide or the like; a derivative formed by the reaction of the compound (Ik) with phosphorus trichloride or phosgene, and the like.
- Suitable reactive derivative of the compound (XXXVI) may include an acid halide, an acid anhydride, an activated amide, an activated ester, isocyanate, and the like.
- the suitable example may be an acid chloride, an acid azide; a mixed acid anhydride with an acid such as substituted phosphoric acid (e.g. dialkylphosphoric acid, phenylphosphoric acid, diphenylphosphoric acid, dibenzylphosphoric acid, halogenated phosphoric acid, etc.), dialkylphosphorous acid, sulfurous acid, thiosulfuric acid, alkanesulfonic acid (e.g.
- methanesulfonic acid ethanesulfonic acid, etc.
- sulfuric acid alkylcarbonic acid, aliphatic carboxylic acid (e.g. pivalic acid, pentanoic acid, isopentanoic acid, 2-ethylbutyric acid or trichloroacetic acid, etc.) or aromatic carboxylic acid (e.g. benzoic acid, etc.); a symmetrical acid anhydride; an activated amide with imidazole, 4-substituted imidazole, dimethylpyrazole, triazole or tetrazole, or an activated ester (e.g.
- the reaction is usually carried out in a conventional solvent such as water, acetone, dioxane, acetonitrile, chloroform, methylene chloride, ethylene chloride, tetrahydrofuran, ethyl acetate, N,N-dimethylformamide pyridine or any other organic solvents which do not adversely influence the reaction.
- a conventional solvent such as water, acetone, dioxane, acetonitrile, chloroform, methylene chloride, ethylene chloride, tetrahydrofuran, ethyl acetate, N,N-dimethylformamide pyridine or any other organic solvents which do not adversely influence the reaction.
- a conventional solvent such as water, acetone, dioxane, acetonitrile, chloroform, methylene chloride, ethylene chloride, tetrahydrofuran, ethyl acetate, N,N-dimethylformamide pyridine or any other
- the reaction is preferably carried out in the presence of a conventional condensing agent such as N,N'-dicyclohexylcarbodiimide; N-cyclohexyl-N'-morpholinoethylcarbodiimide; N-cyclohexyl-N'-(4-diethylaminocyclohexyl)carbodiimide; N,N'-diethylcarbodiimide, N,N'-diisopropylcarbodiimide; N-ethyl-N'-(3-dimethylaminopropyl)carbodiimide; N,N-carbonylbis-(2-methylimidazole); pentamethyleneketene-N-cyclohexylimine, diphenylketene-N-cyclohexylimine; ethoxyacetylene; 1-alkoxy-1-chloroethylene
- the reaction may also be carried out in the presence of an inorganic or organic base such as an alkali metal bicarbonate, tri(lower)alkylamine (e.g., trimethylamine, triethylamine, etc.), pyridine, N-(lower)alkylmorphorine, N,N-di(lower)alkylbenzylamine, or the like.
- an inorganic or organic base such as an alkali metal bicarbonate, tri(lower)alkylamine (e.g., trimethylamine, triethylamine, etc.), pyridine, N-(lower)alkylmorphorine, N,N-di(lower)alkylbenzylamine, or the like.
- the reaction temperature is not critical, and the reaction is usually carried out under cooling to heating.
- the compound (Iu) or a salt thereof can be prepared by reacting the compound (IIa) or a salt thereof with the compound (XXVIII) or a salt thereof.
- This reaction is usually carried out in a solvent such as water, alcohol (e.g., methanol, ethanol, etc.), benzene, N,N-dimethylformamide, tetrahydrofuran, toluene, methylene chloride, ethylene dichloride, chloroform, dioxane, diethyl ether or any other solvent which does not adversely affect the reaction.
- a solvent such as water, alcohol (e.g., methanol, ethanol, etc.), benzene, N,N-dimethylformamide, tetrahydrofuran, toluene, methylene chloride, ethylene dichloride, chloroform, dioxane, diethyl ether or any other solvent which does not adversely affect the reaction.
- solvent such as water, alcohol (e.g., methanol, ethanol, etc.), benzene, N,N-dimethylformamide, tetrahydrofuran, toluene,
- the reaction temperature is not critical and the reaction is usually carried out under warming to heating.
- the reaction is usually carried out in the presence of an acid including Lewis acid.
- Suitable acid may include an organic acid [e.g. formic acid, acetic acid, propionic acid, trichloroacetic acid, trifluoroacetic acid, etc.], an inorganic acid [e.g. hydrochloric acid, hydrobromic acid, sulfuric acid, hydrogen chloride, hydrogen bromide, zinc halide (e.g. zinc chloride, zinc bromide, etc.), etc.] and the like.
- organic acid e.g. formic acid, acetic acid, propionic acid, trichloroacetic acid, trifluoroacetic acid, etc.
- an inorganic acid e.g. hydrochloric acid, hydrobromic acid, sulfuric acid, hydrogen chloride, hydrogen bromide, zinc halide (e.g. zinc chloride, zinc bromide, etc.), etc.
- the acid and/or the starting compound are in liquid, they can be also used as a solvent.
- the compound (Iv) or a salt thereof can be prepared by reacting the compound (IIa) or a salt thereof with the compound (XXIX) or a salt thereof.
- This reaction is usually carried out in a solvent such as water, alcohol (e.g., methanol, ethanol, etc.), benzene, N,N-dimethylformamide, tetrahydrofuran, toluene, methylene chloride, ethylene dichloride, chloroform, diethyl ether or any other solvent which does not adversely affect the reaction.
- a solvent such as water, alcohol (e.g., methanol, ethanol, etc.), benzene, N,N-dimethylformamide, tetrahydrofuran, toluene, methylene chloride, ethylene dichloride, chloroform, diethyl ether or any other solvent which does not adversely affect the reaction.
- the reaction temperature is not critical and the reaction is usually carried out under warming to heating.
- the starting compound when in liquid, it can be also used as a solvent.
- the compound (Iw) or a salt thereof can be prepared by reacting the compound (IIa) or a salt thereof with the compound (XXX) or a salt thereof.
- This reaction is usually carried out in a solvent such as water, alcohol (e.g., methanol, ethanol, etc.), benzene, N,N-dimethylformamide, tetrahydrofuran, toluene, methylene chloride, ethylene dichloride, chloroform, diethyl ether or any other solvent which does not adversely affect the reaction.
- a solvent such as water, alcohol (e.g., methanol, ethanol, etc.), benzene, N,N-dimethylformamide, tetrahydrofuran, toluene, methylene chloride, ethylene dichloride, chloroform, diethyl ether or any other solvent which does not adversely affect the reaction.
- the reaction temperature is not critical and the reaction is usually carried out under warming to heating.
- the compound (Ix) or a salt thereof can be prepared by reacting the compound (IIa) or a salt thereof with the compound (XXXI) or a salt thereof.
- This reaction is usually carried out in a solvent such as water, alcohol (e.g., methanol, ethanol, etc.), benzene, N,N-dimethylformamide, tetrahydrofuran, toluene, methylene chloride, ethylene dichloride, chloroform, dioxane, diethyl ether or any other solvent which does not adversely affect the reaction.
- a solvent such as water, alcohol (e.g., methanol, ethanol, etc.), benzene, N,N-dimethylformamide, tetrahydrofuran, toluene, methylene chloride, ethylene dichloride, chloroform, dioxane, diethyl ether or any other solvent which does not adversely affect the reaction.
- solvent such as water, alcohol (e.g., methanol, ethanol, etc.), benzene, N,N-dimethylformamide, tetrahydrofuran, toluene,
- the reaction temperature is not critical and the reaction is usually carried out under warming to heating.
- the reaction is usually carried out in the presence of an acid including Lewis acid.
- Suitable acid may include an organic acid [e.g. formic acid, acetic acid, propionic acid, trichloroacetic acid, trifluoroacetic acid, etc.], an inorganic acid [e.g. hydrochloric acid, hydrobromic acid, sulfuric acid, hydrogen chloride, hydrogen bromide, zinc halide (e.g. zinc chloride, zinc bromide, etc.), etc.] and the like.
- organic acid e.g. formic acid, acetic acid, propionic acid, trichloroacetic acid, trifluoroacetic acid, etc.
- an inorganic acid e.g. hydrochloric acid, hydrobromic acid, sulfuric acid, hydrogen chloride, hydrogen bromide, zinc halide (e.g. zinc chloride, zinc bromide, etc.), etc.
- the acid and/or the starting compound are in liquid, they can be also used as a solvent.
- the compound (Iy) or a salt thereof can be prepared by reacting the compound (II) or a salt thereof with the compound (XXXII) or a salt thereof.
- This reaction is usually carried out in a solvent such as water, alcohol (e.g., methanol, ethanol, etc.), benzene, N,N-dimethylformamide, tetrahydrofuran, toluene, methylene chloride, ethylene dichloride, chloroform, dioxane, diethyl ether or any other solvent which does not adversely affect the reaction.
- a solvent such as water, alcohol (e.g., methanol, ethanol, etc.), benzene, N,N-dimethylformamide, tetrahydrofuran, toluene, methylene chloride, ethylene dichloride, chloroform, dioxane, diethyl ether or any other solvent which does not adversely affect the reaction.
- solvent such as water, alcohol (e.g., methanol, ethanol, etc.), benzene, N,N-dimethylformamide, tetrahydrofuran, toluene,
- the reaction temperature is not critical and the reaction is usually carried out under warming to heating.
- the reaction is usually carried out in the presence of an acid including Lewis acid.
- Suitable acid may include an organic acid [e.g. formic acid, acetic acid, propionic acid, trichloroacetic acid, trifluoroacetic acid, etc.], an inorganic acid [e.g. hydrochloric acid, hydrobromic acid, sulfuric acid, hydrogen chloride, hydrogen bromide, zinc halide (e.g. zinc chloride, zinc bromide, etc.), etc.] and the like.
- organic acid e.g. formic acid, acetic acid, propionic acid, trichloroacetic acid, trifluoroacetic acid, etc.
- an inorganic acid e.g. hydrochloric acid, hydrobromic acid, sulfuric acid, hydrogen chloride, hydrogen bromide, zinc halide (e.g. zinc chloride, zinc bromide, etc.), etc.
- the acid and/or the starting compound are in liquid, they can be also used as a solvent.
- the compound (Iz) or a salt thereof can be prepared by reacting the compound (II) or a salt thereof with the compound (XXXIII) or a salt thereof.
- This reaction is usually carried out in a solvent such as water, alcohol (e.g., methanol, ethanol, etc.), benzene, N,N-dimethylformamide, tetrahydrofuran, toluene, methylene chloride, ethylene dichloride, chloroform, dioxane, diethyl ether or any other solvent which does not adversely affect the reaction.
- a solvent such as water, alcohol (e.g., methanol, ethanol, etc.), benzene, N,N-dimethylformamide, tetrahydrofuran, toluene, methylene chloride, ethylene dichloride, chloroform, dioxane, diethyl ether or any other solvent which does not adversely affect the reaction.
- solvent such as water, alcohol (e.g., methanol, ethanol, etc.), benzene, N,N-dimethylformamide, tetrahydrofuran, toluene,
- the reaction temperature is not critical and the reaction is usually carried out under warming to heating.
- the reaction is usually carried out in the presence of an acid including Lewis acid.
- Suitable acid may include an organic acid [e.g. formic acid, acetic acid, propionic acid, trichloroacetic acid, trifluoroacetic acid, etc.], an inorganic acid [e.g. hydrochloric acid, hydrobromic acid, sulfuric acid, hydrogen chloride, hydrogen bromide, zinc halide (e.g. zinc chloride, zinc bromide, etc.), etc.] and the like.
- organic acid e.g. formic acid, acetic acid, propionic acid, trichloroacetic acid, trifluoroacetic acid, etc.
- an inorganic acid e.g. hydrochloric acid, hydrobromic acid, sulfuric acid, hydrogen chloride, hydrogen bromide, zinc halide (e.g. zinc chloride, zinc bromide, etc.), etc.
- the acid and/or the starting compound are in liquid, they can be also used as a solvent.
- the compound (Ij) or a salt thereof can be prepared by reacting the compound (IIa) or a salt thereof with the compound (XXXIV) or a salt thereof.
- This reaction is usually carried out in a solvent such as water, alcohol (e.g., methanol, ethanol, etc.), benzene, N,N-dimethylformamide, tetrahydrofuran, toluene, methylene chloride, ethylene dichloride, chloroform, dioxane, diethyl ether or any other solvent which does not adversely affect the reaction.
- a solvent such as water, alcohol (e.g., methanol, ethanol, etc.), benzene, N,N-dimethylformamide, tetrahydrofuran, toluene, methylene chloride, ethylene dichloride, chloroform, dioxane, diethyl ether or any other solvent which does not adversely affect the reaction.
- solvent such as water, alcohol (e.g., methanol, ethanol, etc.), benzene, N,N-dimethylformamide, tetrahydrofuran, toluene,
- the reaction temperature is not critical and the reaction is usually carried out under warming to heating.
- the reaction is usually carried out in the presence of an acid including Lewis acid.
- Suitable acid may include an organic acid [e.g. formic acid, acetic acid, propionic acid, trichloroacetic acid, trifluoroacetic acid, etc.], an inorganic acid [e.g. hydrochloric acid, hydrobromic acid, sulfuric acid, hydrogen chloride, hydrogen bromide, zinc halide (e.g. zinc chloride, zinc bromide, etc.), etc.] and the like.
- organic acid e.g. formic acid, acetic acid, propionic acid, trichloroacetic acid, trifluoroacetic acid, etc.
- an inorganic acid e.g. hydrochloric acid, hydrobromic acid, sulfuric acid, hydrogen chloride, hydrogen bromide, zinc halide (e.g. zinc chloride, zinc bromide, etc.), etc.
- the acid and/or the starting compound are in liquid, they can be also used as a solvent.
- the compound (Is) or a salt thereof can be prepared by reacting the compound (II) or a salt thereof with the compound (XXXV) or a salt thereof.
- This reaction is usually carried out in a solvent such as water, alcohol (e.g., methanol, ethanol, etc.), benzene, N,N-dimethylformamide, tetrahydrofuran, toluene, methylene chloride, ethylene dichloride, chloroform, dioxane, diethyl ether or any other solvent which does not adversely affect the reaction.
- a solvent such as water, alcohol (e.g., methanol, ethanol, etc.), benzene, N,N-dimethylformamide, tetrahydrofuran, toluene, methylene chloride, ethylene dichloride, chloroform, dioxane, diethyl ether or any other solvent which does not adversely affect the reaction.
- solvent such as water, alcohol (e.g., methanol, ethanol, etc.), benzene, N,N-dimethylformamide, tetrahydrofuran, toluene,
- the reaction temperature is not critical and the reaction is usually carried out under warming to heating.
- the reaction is usually carried out in the presence of an acid including Lewis acid.
- Suitable acid may include an organic acid [e.g. formic acid, acetic acid, propionic acid, trichloroacetic acid, trifluoroacetic acid, etc.], an inorganic acid [e.g. hydrochloric acid, hydrobromic acid, sulfuric acid, hydrogen chloride, hydrogen bromide, zinc halide (e.g. zinc chloride, zinc bromide, etc.), etc.] and the like.
- organic acid e.g. formic acid, acetic acid, propionic acid, trichloroacetic acid, trifluoroacetic acid, etc.
- an inorganic acid e.g. hydrochloric acid, hydrobromic acid, sulfuric acid, hydrogen chloride, hydrogen bromide, zinc halide (e.g. zinc chloride, zinc bromide, etc.), etc.
- the acid and/or the starting compound are in liquid, they can be also used as a solvent.
- the compound (VII) or a salt thereof can be prepared by reacting the compound (V) or a salt thereof with the compound (VI) or a salt thereof.
- This reaction can be carried out in the manner disclosed in Preparation 1 or similar manners thereto.
- the compound (IX) or a salt thereof can be prepared by reacting the compound (VII) or a salt thereof with the compound (VIII) or a salt thereof.
- This reaction can be carried out in the manner disclosed in Preparation 2 or similar manners thereto.
- the compound (X) or a salt thereof can be prepared by subjecting the compound (IX) or a salt thereof to cleavage reaction of O-N bond.
- This reaction can be carried out in the manner disclosed in Preparation 4 or similar manners thereto.
- the compound (XI) or a salt thereof can be prepared by subjecting the compound (X) or a salt thereof to halogenation reaction.
- This halogenation is usually carried out by using a conventional halogenating agent such as halogen (e.g., chlorine, bromine, etc.), phosphorus trihalide (e.g., phosphorus tribromide, phosphorus trichloride, etc.), phosphorus pentahalide, (e.g., phosphorus pentachloride, phosphorus pentabromide, etc.), phosphorus oxychloride (e.g., phosphoryl trichloride, phosphoryl monochloride, etc.), thionyl halide (e.g., thionyl chloride, thionyl bromide, etc.), oxalyl halide (e.g., oxalyl chloride, oxalyl bromide, etc.) and the like.
- halogen e.g., chlorine, bromine, etc.
- phosphorus trihalide e.g., phosphorus tribromide,
- This reaction is usually carried out in a solvent such as water, alcohol (e.g,, methanol, ethanol, isopropyl alcohol, etc.), benzene, dioxane, N,N-dimethylformamide, tetrahydrofuran, methylene chloride, ethylene dichloride, chloroform, diethyl ether or any other solvent which does not adversely affect the reaction.
- a solvent such as water, alcohol (e.g, methanol, ethanol, isopropyl alcohol, etc.), benzene, dioxane, N,N-dimethylformamide, tetrahydrofuran, methylene chloride, ethylene dichloride, chloroform, diethyl ether or any other solvent which does not adversely affect the reaction.
- the reaction temperature is not critical and the reaction is usually carried out under cooling to warming.
- the compound (IIa) or a salt thereof can be prepared by reacting the compound (XI) or a salt thereof with the compound (XII) or a salt thereof.
- This reaction is usually carried out in a solvent such as water, alcohol (e.g., methanol, ethanol, etc.), benzene, N,N-dimethylformamide, tetrahydrofuran, toluene, methylene chloride, ethylene dichloride, chloroform, diethyl ether or any other solvent which does not adversely affect the reaction.
- a solvent such as water, alcohol (e.g., methanol, ethanol, etc.), benzene, N,N-dimethylformamide, tetrahydrofuran, toluene, methylene chloride, ethylene dichloride, chloroform, diethyl ether or any other solvent which does not adversely affect the reaction.
- the reaction temperature is not critical and the reaction is usually carried out under warming to heating.
- the compound (X) or a salt thereof can be prepared by reacting the compound (XXII) or a salt thereof with the compound (XXIII) or a salt thereof.
- This reaction is usually carried out in a solvent such as water, alcohol (e.g., methanol, ethanol, etc.), benzene, N,N-dimethylformamide, tetrahydrofuran, toluene, methylene chloride, ethylene dichloride, chloroform, dioxane, diethyl ether or any other solvent which does not adversely affect the reaction.
- a solvent such as water, alcohol (e.g., methanol, ethanol, etc.), benzene, N,N-dimethylformamide, tetrahydrofuran, toluene, methylene chloride, ethylene dichloride, chloroform, dioxane, diethyl ether or any other solvent which does not adversely affect the reaction.
- solvent such as water, alcohol (e.g., methanol, ethanol, etc.), benzene, N,N-dimethylformamide, tetrahydrofuran, toluene,
- the reaction temperature is not critical and the reaction is usually carried out under warming to heating.
- the reaction is usually carried out in the presence of an inorganic or an organic base such as an alkali metal (e.g., sodium, potassium, etc.), an alkali metal hydroxide (e.g., sodium hydroxide, potassium hydroxide, etc.), an alkali metal hydrogencarbonate (e.g., sodium hydrogencarbonate, potassium hydrogencarbonate, etc.), alkali metal carbonate (e.g., sodium carbonate, potassium carbonate, etc.), tri(lower)alkylamine (e.g., trimethylamine, triethylamine, diisopropylethylamine, etc.), alkali metal hydride (e.g., sodium hydride, etc.), alkali metal (lower)alkoxide (e.g., sodium methoxide, sodium ethoxide, etc.), pyridine lutidine, picoline, dimethylaminopyridine, N-(lower)alkylmorpholine, N,N-di(lower)al
- the base and/or the starting compound When the base and/or the starting compound are in liquid, they can be also as a solvent.
- the compound (IIa) or a salt thereof can be prepared by reacting the compound (X) or a salt thereof with the compound (XII) or a salt thereof.
- This reaction is usually carried out in a solvent such as benzene, N,N-dimethylformamide, tetrahydrofuran, toluene, methylene chloride, ethylene dichloride, chloroform, dioxane, diethyl ether or any other solvent which does not adversely affect the reaction.
- a solvent such as benzene, N,N-dimethylformamide, tetrahydrofuran, toluene, methylene chloride, ethylene dichloride, chloroform, dioxane, diethyl ether or any other solvent which does not adversely affect the reaction.
- the reaction temperature is not critical and the reaction is usually carried out under warming to heating.
- the reaction is usually carried out in the presence of an acid including Lewis acid.
- Suitable acid may include an organic acid [e.g. formic acid, acetic acid, propionic acid, trichloroacetic acid, trifluoroacetic acid, etc.], an inorganic acid [e.g. hydrochloric acid, hydrobromic acid, sulfuric acid, hydrogen chloride, hydrogen bromide, zinc halide (e.g. zinc chloride, zing bromide, etc.), etc.] and the like.
- organic acid e.g. formic acid, acetic acid, propionic acid, trichloroacetic acid, trifluoroacetic acid, etc.
- an inorganic acid e.g. hydrochloric acid, hydrobromic acid, sulfuric acid, hydrogen chloride, hydrogen bromide, zinc halide (e.g. zinc chloride, zing bromide, etc.), etc.
- the acid and/or the starting compound When the acid and/or the starting compound are in liquid, they can be also as a solvent.
- the compound (XIII) or a salt thereof can be prepared by reacting the compound (II) or a salt thereof with the compound (XXIV) or a salt thereof.
- This reaction is usually carried out in a solvent such as water, alcohol (e.g., methanol, ethanol, etc.), benzene, N,N-dimethylformamide, tetrahydrofuran, toluene, methylene chloride, ethylene dichloride, chloroform, diethyl ether or any other solvent which does not adversely affect the reaction.
- a solvent such as water, alcohol (e.g., methanol, ethanol, etc.), benzene, N,N-dimethylformamide, tetrahydrofuran, toluene, methylene chloride, ethylene dichloride, chloroform, diethyl ether or any other solvent which does not adversely affect the reaction.
- the reaction temperature is not critical and the reaction is usually carried out under cooling to warming.
- the compound (XV) or a salt thereof can be prepared by reacting the compound (XXV) or a salt thereof with the compound (XXVI) or a salt thereof.
- This reaction is usually carried out in a solvent such as benzene, tetrahydrofuran, toluene, methylene chloride, ethylene dichloride, chloroform, diethyl ether or any other solvent which does not adversely affect the reaction.
- a solvent such as benzene, tetrahydrofuran, toluene, methylene chloride, ethylene dichloride, chloroform, diethyl ether or any other solvent which does not adversely affect the reaction.
- the reaction temperature is not critical and the reaction is usually carried out under cooling to heating.
- the reaction may be also carried out in the presence of a strong inorganic or a strong organic base such as an alkali metal (e.g., sodium, etc.), alkali metal hydride (e.g. sodium hydride, etc.) or the like.
- a strong inorganic or a strong organic base such as an alkali metal (e.g., sodium, etc.), alkali metal hydride (e.g. sodium hydride, etc.) or the like.
- the base and/or the starting compound When the base and/or the starting compound are in liquid, they can be also as a solvent.
- the compound (XVI) or a salt thereof can be prepared by subjecting the compound (IIa) or a salt thereof to diazotization reaction.
- the reaction is usually carried out by using a conventional diazotizing agent such as a combination of an alkali metal nitrite (e.g., sodium nitrite, etc.) and an inorganic acid (e.g., hydrochloric acid, hydrobromic acid, nitric acid, sulfuric acid, etc.), a combination of isopentyl nitrite and an organic acid (e.g., acetic acid, benzoic acid, etc.) and the like.
- a conventional diazotizing agent such as a combination of an alkali metal nitrite (e.g., sodium nitrite, etc.) and an inorganic acid (e.g., hydrochloric acid, hydrobromic acid, nitric acid, sulfuric acid, etc.), a combination of isopentyl nitrite and an organic acid (e.g., acetic acid, benzoic acid, etc.) and the like.
- This reaction is usually carried out in a solvent such as water, alcohol (e.g., methanol, ethanol, etc.), benzene, N,N-dimethylformamide, tetrahydrofuran, toluene, methylene chloride, ethylene dichloride, chloroform, diethyl ether or any other solvent which does not adversely affect the reaction.
- a solvent such as water, alcohol (e.g., methanol, ethanol, etc.), benzene, N,N-dimethylformamide, tetrahydrofuran, toluene, methylene chloride, ethylene dichloride, chloroform, diethyl ether or any other solvent which does not adversely affect the reaction.
- the reaction temperature is not critical and the reaction is usually carried out under cooling.
- the compound (XXVIIa) or a salt thereof can be prepared by reacting the compound (II) or a salt thereof with the compound (XVIII) or a salt thereof.
- This reaction is usually carried out in a solvent such as water, alcohol (e.g., methanol, ethanol, etc.), benzene, N,N-dimethylformamide, tetrahydrofuran, toluene, methylene chloride, ethylene dichloride, chloroform, dioxane, diethyl ether or any other solvent which does not adversely affect the reaction.
- a solvent such as water, alcohol (e.g., methanol, ethanol, etc.), benzene, N,N-dimethylformamide, tetrahydrofuran, toluene, methylene chloride, ethylene dichloride, chloroform, dioxane, diethyl ether or any other solvent which does not adversely affect the reaction.
- solvent such as water, alcohol (e.g., methanol, ethanol, etc.), benzene, N,N-dimethylformamide, tetrahydrofuran, toluene,
- the reaction temperature is not critical and the reaction is usually carried out under cooling to heating.
- the reaction is usually carried out in the presence of an inorganic or an organic base such as an alkali metal (e.g. sodium, potassium, etc.), an alkali metal hydroxide (e.g., sodium hydroxide, potassium hydroxide, etc.), an alkali metal hydrogencarbonate (e.g., sodium hydrogencarbonate, potassium hydrogencarbonate, etc.), alkali metal carbonate (e.g., sodium carbonate, potassium carbonate, etc.), tri(lower)alkylamine (e.g., trimethylamine, triethylamine, diisopropylethylamine, etc.), alkali metal hydride (e.g., sodium hydride, etc.), alkali metal (lower)alkoxide (e.g., sodium methoxide, sodium ethoxide, etc.), pyridine, lutidine, picoline, dimethylaminopyridine, N-(lower)alkylmorpholine, N,N-di(lower)al
- the base and/or the starting compound When the base and/or the starting compound are in liquid, they can be also as a solvent.
- Suitable salts of the object and starting compounds in Process (1)-(22) and (A)-(J) can be referred to the ones as exemplified for the compound (I).
- the new pyrazole derivatives (I) and a pharmaceutically acceptable salt thereof of the present invention possess a strong inhibitory activity on the production of Interleukin-1 (IL-1) and a strong inhibitory activity on the production of tumor necrosis factor (TNF), and therefore are useful as an inhibitor on the production of Interleukin-1 (IL-1) and an inhibitor on the production of tumor necrosis factor (TNF).
- IL-1 Interleukin-1
- TNF tumor necrosis factor
- the new pyrazole derivatives (I) and a pharmaceutically acceptable salt thereof can be used for prophylactic and therapeutic treatment of IL-1 and TNF mediated diseases such as chronic inflammatory diseases (e.g. rheumatoid arthritis, osteoarthritis, etc.) osteoporosis, rejection by transplantation, asthma, endotoxin shock, specific autoimmune diseases [e.g. ankylosing spondylitis, autoimmune hematological disorders (e.g.
- hemolyticodo anaemia aplastic anaemia, pure red cell anaemia, idiopathic thrombocytopenia, etc.
- systemic lupus erythematosus polychondritis, scleroderma, Wegener granulamotosis, dermatomyositis, chronic active hepatitis, myasthenia gravis, psoriasis, idiopathic sprue, autoimmune inflammatory bowel disease (e.g.
- ulcerative colitis, Crohn's disease, etc. endocrine opthalmopathy, Grave's disease, sarcoidosis, multiple scleosis, primary billiary cirrhosis, juvenile diabetes (diabetes mellitus type I), Reiter's syndrome, non infection uveitis, autoimmune keratitis (e.g. keratoconjuntivitis sicca, vernal keratoconjunctivitis, etc.), interstitial lung fibrosis, psoriatic arthritis, glomerulonephritis ⁇ e.g. nephrotic syndrome (e.g. idiopathic nephrotic syndrome, minimal change nephropathy, etc.), etc. ⁇ , etc.), cancer cachexia, AIDS cachexia, and the like.
- autoimmune keratitis e.g. keratoconjuntivitis sicca, vernal keratoconjunctivitis, etc.
- Example 2-(1) in the following test means the compound prepared in Example 2-(1).
- Purified human peripheral blood monocyte were stimulated with bacterial lipopolysaccharide (1 ⁇ g/104 cells) in the absence or presence of appropriately diluted test compound for 2 days at 37°C in a humidified 5% CO2 atmosphere. Culture supernatants were tested for IL-1 ELISA assay.
- Test compound was dissolved in absolute DMSO (dimethyl sulfoxide) to achieve 10 mM stock solutions and was subsequently diluted in serum free RPMI1640.
- IL-1 levels were quantified by a commercial ELISA kit (Ohtsuka assay, Japan) using a sandwich technique.
- the sensitivity levels for the detection of IL-1 ⁇ were 20 pg/ml.
- the inhibitory concentration that caused a 50% inhibition was calculated by regression analysis of the dose-response data.
- Test compound IC50 (M) Example 2-(1) 3.8 x 10 ⁇ 8
- Purified human peripheral blood monocyte were stimulated with bacterial lipopolysaccharide (1 ⁇ g/104 cells) in the absence or presence of appropriately diluted test compound for 2 days at 37°C in a humidified 5% CO2 atmosphere. Culture supernatants were tested for TNF ELISA assay.
- TNF levels were quantified by a commercial ELISA kit (Endogen, Inc. USA) using a sandwich technique.
- the sensitivity levels for the detection of TNF were 12 pg/ml.
- the inhibitory concentration that caused a 50% inhibition was calculated by regression analysis of the dose-response data.
- Test compound IC50 (M) Example 2-(1) 1.16 x 10 ⁇ 7
- the object compounds (I) of the present invention and pharmaceutically acceptable salts thereof are used in a form of the conventional pharmaceutical preparation in admixture with a conventional pharmaceutically acceptable carrier such as an organic or inorganic solid or liquid excipient which is suitable for oral, parenteral or external administration.
- a conventional pharmaceutically acceptable carrier such as an organic or inorganic solid or liquid excipient which is suitable for oral, parenteral or external administration.
- the pharmaceutical preparation may be compounded in a solid form such as granule, capsule, tablet, dragee or suppository, or in a liquid form such as solution, suspension or emulsion for injection, ingestion, eye drops, etc. If needed, there may be included in the above preparation auxiliary substance such as stabilizing agent, wetting or emulsifying agent, buffer or any other commonly used additives.
- the effective ingredient may usually be administered with a unit dose of 0.001 mg/kg to 500 mg/kg, preferably 0.01 mg/kg to 10 mg/kg, 1 to 4 times a day.
- the above dosage may be increased or decreased according to age, weight and conditions of the patient or the administering method.
- Preferred embodiments of the object compound (I) are as follows.
- Example 2-(1) The following compounds were obtained according to a similar manner to that of Example 2-(1).
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Public Health (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GB919119267A GB9119267D0 (en) | 1991-09-09 | 1991-09-09 | Pyrazole derivatives |
| GB9119267 | 1991-09-09 | ||
| GB929204464A GB9204464D0 (en) | 1992-03-02 | 1992-03-02 | New heterocyclic derivatives |
| GB9204464 | 1992-03-02 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| EP0531901A2 true EP0531901A2 (de) | 1993-03-17 |
| EP0531901A3 EP0531901A3 (de) | 1993-05-05 |
Family
ID=26299519
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| EP19920115154 Withdrawn EP0531901A3 (de) | 1991-09-09 | 1992-09-02 | Kondensierte Pyrazolderivate mit Interleukin-1 und Tumor Necrosis Faktor Inhibitor Wirkung |
Country Status (10)
| Country | Link |
|---|---|
| US (3) | US5356897A (de) |
| EP (1) | EP0531901A3 (de) |
| JP (2) | JPH0788386B2 (de) |
| CN (1) | CN1070404A (de) |
| AU (1) | AU2280592A (de) |
| CA (1) | CA2077732A1 (de) |
| HU (1) | HUT65204A (de) |
| IL (1) | IL102946A0 (de) |
| MX (1) | MX9205145A (de) |
| TW (1) | TW257763B (de) |
Cited By (52)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO1994019350A1 (en) * | 1993-02-26 | 1994-09-01 | Fujisawa Pharmaceutical Co., Ltd. | Pyrazolitriazines with interleukin-1 and tumour necrosis factor inhibitory activity |
| WO1995001980A1 (en) * | 1993-07-06 | 1995-01-19 | Pfizer Inc. | Bicyclic tetrahydro pyrazolopyridines |
| WO1998003510A1 (en) * | 1996-07-24 | 1998-01-29 | Du Pont Pharmaceuticals Company | Azolo triazines and pyrimidines |
| US5723481A (en) * | 1988-07-26 | 1998-03-03 | Sankyo Company, Limited | Use of imidazopyrazole derivatives as analgesics and anti-inflammatory agents |
| WO1998052937A3 (en) * | 1997-05-22 | 1999-03-11 | Searle & Co | 4-aryl-3(5)-heteroaryl substituted pyrazoles as p38 kinase |
| RU2147584C1 (ru) * | 1995-10-27 | 2000-04-20 | Американ Цианамид Компани | Способ получения дигалоидазолопиримидинов и способ получения дигидроксиазолопиримидинов |
| US6060478A (en) * | 1996-07-24 | 2000-05-09 | Dupont Pharmaceuticals | Azolo triazines and pyrimidines |
| WO2000031063A1 (en) * | 1998-11-20 | 2000-06-02 | G.D. Searle & Co. | SUBSTITUTED PYRAZOLES AS p38 KINASE INHIBITORS |
| US6087496A (en) * | 1998-05-22 | 2000-07-11 | G. D. Searle & Co. | Substituted pyrazoles suitable as p38 kinase inhibitors |
| US6124289A (en) * | 1996-07-24 | 2000-09-26 | Dupont Pharmaceuticals Co. | Azolo triazines and pyrimidines |
| US6191131B1 (en) | 1997-07-23 | 2001-02-20 | Dupont Pharmaceuticals Company | Azolo triazines and pyrimidines |
| WO2001016138A1 (en) * | 1999-08-27 | 2001-03-08 | Abbott Laboratories | Sulfonylphenylpyrazole compounds useful as cox-2 inhibitors |
| WO2001015525A1 (en) * | 1999-08-31 | 2001-03-08 | Fujisawa Pharmaceutical Co., Ltd. | Organ preservatives |
| US6313124B1 (en) | 1997-07-23 | 2001-11-06 | Dupont Pharmaceuticals Company | Tetrazine bicyclic compounds |
| RU2178415C2 (ru) * | 1995-12-01 | 2002-01-20 | Американ Цианамид Компани | Усовершенствованный способ получения n-[3-(3-цианопиразоло[1,5-а]пиримидин-7-ил)фенил]-n-этил-ацетамида |
| US6387924B2 (en) | 1994-09-13 | 2002-05-14 | G.D. Searle & Co. | Benzothiepines having activity as inhibitors of ileal bile acid transport and taurocholate uptake |
| US6420417B1 (en) | 1994-09-13 | 2002-07-16 | G. D. Searle & Co. | Combination therapy employing ileal bile acid transport inhibiting benzothiepines and HMG Co-A reductase inhibitors |
| US6458850B1 (en) | 1998-12-23 | 2002-10-01 | G.D. Searle, Llc | Combinations of cholesteryl ester transfer protein inhibitors and fibric acid derivatives for cardiovascular indications |
| US6458851B1 (en) | 1998-12-23 | 2002-10-01 | G. D. Searle, Llc | Combinations of ileal bile acid transport inhibitors and cholesteryl ester transfer protein inhibitors for cardiovascular indications |
| US6462091B1 (en) | 1998-12-23 | 2002-10-08 | G.D. Searle & Co. | Combinations of cholesteryl ester transfer protein inhibitors and HMG coA reductase inhibitors for cardiovascular indications |
| US6472416B1 (en) | 1999-08-27 | 2002-10-29 | Abbott Laboratories | Sulfonylphenylpyrazole compounds useful as COX-2 inhibitors |
| WO2002094833A1 (en) * | 2001-05-24 | 2002-11-28 | Eli Lilly And Company | Novel pyrrole derivatives as pharmaceutical agents |
| US6489366B1 (en) | 1998-12-23 | 2002-12-03 | G. D. Searle, Llc | Combinations of cholesteryl ester transfer protein inhibitors and nicotinic acid derivatives for cardiovascular indications |
| US6503930B1 (en) | 1997-05-22 | 2003-01-07 | G.D. Searle & Company | Pyrazole derivatives as p38 kinase inhibitors |
| US6562860B1 (en) | 1998-12-23 | 2003-05-13 | G. D. Searle & Co. | Combinations of ileal bile acid transport inhibitors and bile acid sequestering agents for cardiovascular indications |
| DE10153344A1 (de) * | 2001-10-29 | 2003-05-15 | Gruenenthal Gmbh | Verwendung von substituierten Pyrazolopyrimidinen als Liganden von Nucleosid-Transport-Proteinen und/oder von Purinorezeptoren |
| US6569905B1 (en) | 1998-12-23 | 2003-05-27 | G.D. Searle, Llc | Combinations of cholesteryl ester transfer protein inhibitors and bile acid sequestering agents for cardiovascular indications |
| US6586434B2 (en) | 2000-03-10 | 2003-07-01 | G.D. Searle, Llc | Method for the preparation of tetrahydrobenzothiepines |
| WO2003053976A1 (en) * | 2001-12-20 | 2003-07-03 | Biovitrum Ab | PIPAZOLO [1,5-a] PYRIMIDINE DERIVATIVES AS MODULATORS OF PPAR |
| US6630476B2 (en) | 2000-07-07 | 2003-10-07 | Bristol-Myers Squibb Pharma Company | Pyrrolo [3,4-d] pyrimidines as corticotropin releasing factor (CRF) antagonists |
| US6638969B1 (en) | 1998-12-23 | 2003-10-28 | G.D. Searle, Llc | Combinations of ileal bile acid transport inhibitors and fibric acid derivatives for cardiovascular indications |
| US6642268B2 (en) | 1994-09-13 | 2003-11-04 | G.D. Searle & Co. | Combination therapy employing ileal bile acid transport inhibiting benzothipines and HMG Co-A reductase inhibitors |
| WO2003095455A3 (en) * | 2002-05-10 | 2003-12-24 | Smithkline Beecham Corp | Substituted pyrazolopyrimidines |
| US6740663B2 (en) | 2001-11-02 | 2004-05-25 | G.D. Searle, Llc | Mono- and di-fluorinated benzothiepine compounds as inhibitors of apical sodium co-dependent bile acid transport (ASBT) and taurocholate uptake |
| WO2004048383A1 (en) * | 2002-11-21 | 2004-06-10 | Eli Lilly And Company | Mixed lineage kinase modulators |
| WO2004048382A1 (en) * | 2002-11-22 | 2004-06-10 | Eli Lilly And Company | Quinolinyl-pyrrolopyrazoles |
| US6852753B2 (en) | 2002-01-17 | 2005-02-08 | Pharmacia Corporation | Alkyl/aryl hydroxy or keto thiepine compounds as inhibitors of apical sodium co-dependent bile acid transport (ASBT) and taurocholate uptake |
| US6958341B2 (en) | 1999-04-06 | 2005-10-25 | Bristol-Myers Squibb Pharma Company | Pyrazolopyrimidines as CRF antagonists |
| US6960583B2 (en) | 1999-04-06 | 2005-11-01 | Bristol-Myers Squibb Company | Pyrazolotriazines as CRF antagonists |
| US6979686B1 (en) | 2001-12-07 | 2005-12-27 | Pharmacia Corporation | Substituted pyrazoles as p38 kinase inhibitors |
| US7037880B2 (en) | 1996-04-25 | 2006-05-02 | Nissan Chemical Industries, Ltd. | Ethylene derivatives and pesticides containing said derivatives |
| US7094782B1 (en) | 1996-07-24 | 2006-08-22 | Bristol-Myers Squibb Company | Azolo triazines and pyrimidines |
| CZ299451B6 (cs) * | 1996-07-24 | 2008-07-30 | Bristol-Myers Squibb Pharma Company | [1,5-a]-Pyrazolo-1,3,5- triaziny jejich použití afarmaceutické kompozice na jejich bázi |
| US7511065B2 (en) | 2003-11-12 | 2009-03-31 | Eli Lilly And Company | Mixed lineage kinase modulators |
| WO2009076440A3 (en) * | 2007-12-12 | 2009-09-24 | E.I. Du Pont De Nemours And Company | Fungicidal bicyclic pyrazoles |
| WO2011105628A1 (en) * | 2010-02-26 | 2011-09-01 | Mitsubishi Tanabe Pharma Corporation | Pyrazolopyrimidine compounds and their use as pde10 inhibitors |
| EP2402344A1 (de) * | 2010-06-29 | 2012-01-04 | Basf Se | Pyrazolkondensierte bicyclische Verbindungen |
| EP2402339A1 (de) | 2010-06-29 | 2012-01-04 | Basf Se | Pyrazolopyridin-Verbindungen |
| EP2402345A1 (de) * | 2010-06-29 | 2012-01-04 | Basf Se | Pyrazole kondensierte bizyclische Verbindungen |
| WO2013050437A1 (en) | 2011-10-06 | 2013-04-11 | Bayer Intellectual Property Gmbh | Heterocyclylpyri (mi) dinylpyrazole as fungicidals |
| WO2015035062A1 (en) * | 2013-09-05 | 2015-03-12 | Genentech, Inc. | Antiproliferative compounds |
| US12503439B2 (en) | 2022-04-22 | 2025-12-23 | Vertex Pharmaceuticals Incorporated | Heteroaryl compounds for the treatment of pain |
Families Citing this family (43)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6277969B1 (en) * | 1991-03-18 | 2001-08-21 | New York University | Anti-TNF antibodies and peptides of human tumor necrosis factor |
| US5356897A (en) * | 1991-09-09 | 1994-10-18 | Fujisawa Pharmaceutical Co., Ltd. | 3-(heteroaryl)-pyrazololi[1,5-a]pyrimidines |
| ATE177635T1 (de) * | 1993-04-22 | 1999-04-15 | Senju Pharma Co | Wässrige arzneizubereitungen enthaltend argatroban und cyclodextrin oder coffein |
| US6228871B1 (en) | 1995-07-10 | 2001-05-08 | Merck & Co., Inc. | Angiogenesis inhibitors |
| FR2750048B1 (fr) * | 1996-06-21 | 1998-08-14 | Oreal | Compositions de teinture des fibres keratiniques contenant des derives pyrazolo-(1, 5-a)-pyrimidine, procede de teinture, nouveaux derives pyrazolo-(1, 5-a)-pyrimidine et leur procede de preparation |
| EP0912548A1 (de) | 1996-07-11 | 1999-05-06 | Pfizer Inc. | Pyridylpyrrol-derivate verwendbar als interleukin- und tnf- antagonisten |
| US6235741B1 (en) * | 1997-05-30 | 2001-05-22 | Merck & Co., Inc. | Angiogenesis inhibitors |
| EP1473292A1 (de) * | 1997-11-03 | 2004-11-03 | Boehringer Ingelheim Pharmaceuticals, Inc. | Aromatische heterocyclische Verbindungen als antiinflammatorische Mittel |
| EP1028953A1 (de) * | 1997-11-03 | 2000-08-23 | Boehringer Ingelheim Pharmaceuticals Inc. | Aromatische heterocyclische verbindungen als antiinflammatorische mittel |
| US6380203B1 (en) * | 1998-01-14 | 2002-04-30 | Merck & Co., Inc. | Angiogenesis inhibitors |
| AU2006203676B2 (en) * | 1999-08-13 | 2010-04-22 | Vertex Pharmaceuticals Incorporated | Inhibitors of c-JUN N-Terminal Kinases (JNK) and Other Protein Kinases |
| BR0013551A (pt) | 1999-08-13 | 2003-06-17 | Vertex Pharma | Inibidores de cinases n-terminal cjun (jnk) e outras cinases de proteìnas |
| CA2379585C (en) * | 1999-09-30 | 2006-06-20 | James W. Darrow | Certain alkylene diamine-substituted pyrazolo[1,5,-a]-1,5-pyrimidines and pyrazolo[1,5-a]-1,3,5-triazines |
| WO2003004497A1 (en) * | 2001-07-05 | 2003-01-16 | Sumitomo Pharmaceuticals Company, Limited | Novel heterocyclic compound |
| CZ293015B6 (cs) * | 2002-10-25 | 2004-01-14 | Léčiva, A.S. | Způsob výroby N-ethyl-N-[3-(3-methyl-pyrazolo[1,5-a]pyrimidin-7-yl)-fenyl]-acetamidu (zaleplonu) |
| WO2004110454A1 (ja) * | 2003-06-13 | 2004-12-23 | Ishihara Sangyo Kaisha, Ltd. | アデノシンA2a受容体アゴニストの投与が必要な疾患を治療又は予防するための組成物 |
| DE10332487A1 (de) * | 2003-07-16 | 2005-02-10 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Ambroxol für die Behandlung von chronisch nozizeptiven Schmerzen |
| WO2006115509A2 (en) | 2004-06-24 | 2006-11-02 | Novartis Vaccines And Diagnostics Inc. | Small molecule immunopotentiators and assays for their detection |
| TW200639163A (en) | 2005-02-04 | 2006-11-16 | Genentech Inc | RAF inhibitor compounds and methods |
| US7608635B2 (en) * | 2005-08-12 | 2009-10-27 | Synta Pharmaceuticals Corp. | Pyrazole compounds that modulate HSP90 activity |
| WO2007026950A1 (en) * | 2005-09-01 | 2007-03-08 | Astellas Pharma Inc. | Pyridazinone derivatives used for the treatment of pain |
| WO2007129195A2 (en) * | 2006-05-04 | 2007-11-15 | Pfizer Products Inc. | 4-pyrimidine-5-amino-pyrazole compounds |
| AU2007267843B2 (en) | 2006-05-25 | 2011-10-13 | Synta Pharmaceuticals Corp. | Method for treating proliferative disorders associated with protooncogene products |
| JP2010540451A (ja) * | 2007-09-20 | 2010-12-24 | ワイス・エルエルシー | ピラゾロ[5,1−c][1,2,4]トリアジン、その調製法および使用法 |
| WO2010096115A1 (en) * | 2008-10-29 | 2010-08-26 | Apath, Llc | Compounds, compositions and methods for control of hepatitis c viral infections |
| EP2560640A1 (de) | 2010-04-19 | 2013-02-27 | Synta Pharmaceuticals Corp. | Krebstherapie mit einer kombination aus hsp90-inhibitorverbindungen und einem egfr-hemmer |
| CA2853799A1 (en) | 2011-11-02 | 2013-05-10 | Synta Pharmaceuticals Corp. | Cancer therapy using a combination of hsp90 inhibitors with topoisomerase i inhibitors |
| JP2014534228A (ja) | 2011-11-02 | 2014-12-18 | シンタ ファーマシューティカルズ コーポレーション | 白金含有剤とhsp90阻害剤の組合せ療法 |
| US9402831B2 (en) | 2011-11-14 | 2016-08-02 | Synta Pharmaceutical Corp. | Combination therapy of HSP90 inhibitors with BRAF inhibitors |
| JO3407B1 (ar) | 2012-05-31 | 2019-10-20 | Eisai R&D Man Co Ltd | مركبات رباعي هيدرو بيرازولو بيريميدين |
| ES2687481T3 (es) | 2013-03-15 | 2018-10-25 | Chromocell Corporation | Moduladores del canal de sodio para el tratamiento del dolor |
| AU2014318979B2 (en) | 2013-09-10 | 2019-03-28 | Chromocell Corporation | Sodium channel modulators for the treatment of pain and diabetes |
| US10342795B2 (en) * | 2014-03-27 | 2019-07-09 | Janssen Pharmaceutica Nv | Substituted 4,5,6,7-tetrahydro-pyrazolo[1,5-a]pyrimidine derivatives and 2,3-dihydro-1H-imidazo[1,2-b]pyrazole derivatives as ROS1 inhibitors |
| ES2715676T3 (es) | 2014-03-27 | 2019-06-05 | Janssen Pharmaceutica Nv | Derivados de 4,5,6,7-tetrahidro-pirazolo[1,5-a]pirazina sustituidos y derivados de 5,6,7,8-tetrahidro-4h-pirazolo[1,5-a][1,4]diazepina como inhibidores de ros1 |
| CN104140427A (zh) * | 2014-07-05 | 2014-11-12 | 湖南华腾制药有限公司 | 一种四氢吡唑并[1,5-a]嘧啶的制备方法 |
| EP3193610A4 (de) * | 2014-09-09 | 2018-04-04 | Chromocell Corporation | Selektive nav1.7-hemmer zur behandlung von diabetes |
| KR102384652B1 (ko) * | 2015-02-03 | 2022-04-27 | 솔루스첨단소재 주식회사 | 유기 화합물 및 이를 포함하는 유기 전계 발광 소자 |
| JP6832430B2 (ja) | 2016-08-31 | 2021-02-24 | アジオス ファーマシューティカルズ, インコーポレイテッド | 細胞代謝過程の阻害剤 |
| US12479816B2 (en) | 2019-02-08 | 2025-11-25 | University of Pittsburgh—of the Commonwealth System of Higher Education | 20-HETE formation inhibitors |
| BR112022010924A2 (pt) | 2019-12-06 | 2022-09-06 | Vertex Pharma | Tetra-hidrofuranos substituídos como moduladores de canais de sódio |
| EP4146654A1 (de) * | 2020-05-07 | 2023-03-15 | Adorx therapeutics Limited | Antagonisten des adenosin-a2a-rezeptors |
| KR20240023691A (ko) | 2020-08-12 | 2024-02-22 | 스프루스 바이오사이언시스 인코포레이티드 | 다낭성 난소 증후군을 치료하기 위한 방법 및 조성물 |
| SMT202500481T1 (it) | 2021-06-04 | 2026-01-12 | Vertex Pharma | N-(idrossialchil(etero)aril)tetraidrofuran carbossammidi come modulatori di canali del sodio |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS62270584A (ja) * | 1986-04-28 | 1987-11-24 | Yoshitomi Pharmaceut Ind Ltd | 4,7−ジヒドロピラゾロ〔1,5−a〕ピリミジン誘導体 |
| JPS6277387A (ja) * | 1985-09-30 | 1987-04-09 | Yoshitomi Pharmaceut Ind Ltd | 4,7−ジヒドロピラゾロ〔1,5−a〕ピリミジン誘導体 |
| GB8426447D0 (en) * | 1984-10-19 | 1984-11-28 | Kodak Ltd | Photographic colour couplers |
| EP0217142A3 (de) * | 1985-09-30 | 1988-01-07 | Yoshitomi Pharmaceutical Industries, Ltd. | Polyazaheterocyclische Verbindung |
| US4794114A (en) * | 1986-08-19 | 1988-12-27 | Smithkline Beckman Corporation | Inhibition of interleukin-1 production by monocytes and/or macrophages |
| JPH0753730B2 (ja) * | 1988-07-26 | 1995-06-07 | 三共株式会社 | イミダゾピラゾール誘導体 |
| JPH05503919A (ja) * | 1989-06-13 | 1993-06-24 | スミスクライン・ビーチャム・コーポレイション | 単球および/またはマクロファージによるインターロイキン―1または腫瘍壊死因子生成の抑制 |
| US5356897A (en) * | 1991-09-09 | 1994-10-18 | Fujisawa Pharmaceutical Co., Ltd. | 3-(heteroaryl)-pyrazololi[1,5-a]pyrimidines |
-
1992
- 1992-08-17 US US07/931,093 patent/US5356897A/en not_active Expired - Fee Related
- 1992-08-25 IL IL102946A patent/IL102946A0/xx unknown
- 1992-09-02 EP EP19920115154 patent/EP0531901A3/de not_active Withdrawn
- 1992-09-04 TW TW081107007A patent/TW257763B/zh active
- 1992-09-07 AU AU22805/92A patent/AU2280592A/en not_active Abandoned
- 1992-09-08 CA CA002077732A patent/CA2077732A1/en not_active Abandoned
- 1992-09-08 CN CN92110569A patent/CN1070404A/zh active Pending
- 1992-09-08 HU HU9202877A patent/HUT65204A/hu unknown
- 1992-09-09 JP JP4240454A patent/JPH0788386B2/ja not_active Expired - Fee Related
- 1992-09-09 MX MX9205145A patent/MX9205145A/es unknown
-
1994
- 1994-07-01 US US08/269,520 patent/US5478827A/en not_active Expired - Fee Related
-
1995
- 1995-03-06 JP JP7044698A patent/JPH07252256A/ja active Pending
- 1995-06-06 US US08/471,175 patent/US5624931A/en not_active Expired - Fee Related
Cited By (85)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5723481A (en) * | 1988-07-26 | 1998-03-03 | Sankyo Company, Limited | Use of imidazopyrazole derivatives as analgesics and anti-inflammatory agents |
| WO1994019350A1 (en) * | 1993-02-26 | 1994-09-01 | Fujisawa Pharmaceutical Co., Ltd. | Pyrazolitriazines with interleukin-1 and tumour necrosis factor inhibitory activity |
| CN1048015C (zh) * | 1993-07-06 | 2000-01-05 | 美国辉瑞有限公司 | 双环四氢吡唑并吡啶类化合物 |
| WO1995001980A1 (en) * | 1993-07-06 | 1995-01-19 | Pfizer Inc. | Bicyclic tetrahydro pyrazolopyridines |
| US6642268B2 (en) | 1994-09-13 | 2003-11-04 | G.D. Searle & Co. | Combination therapy employing ileal bile acid transport inhibiting benzothipines and HMG Co-A reductase inhibitors |
| US6784201B2 (en) | 1994-09-13 | 2004-08-31 | G.D. Searle & Company | Benzothiepines having activity as inhibitors of ileal bile acid transport and taurocholate uptake |
| US6420417B1 (en) | 1994-09-13 | 2002-07-16 | G. D. Searle & Co. | Combination therapy employing ileal bile acid transport inhibiting benzothiepines and HMG Co-A reductase inhibitors |
| US6387924B2 (en) | 1994-09-13 | 2002-05-14 | G.D. Searle & Co. | Benzothiepines having activity as inhibitors of ileal bile acid transport and taurocholate uptake |
| US6943189B2 (en) | 1994-09-13 | 2005-09-13 | G.D. Searle & Co. | Combination therapy employing ileal bile acid transport inhibiting benzothiepines and HMG CO-A reductase inhibitors |
| RU2147584C1 (ru) * | 1995-10-27 | 2000-04-20 | Американ Цианамид Компани | Способ получения дигалоидазолопиримидинов и способ получения дигидроксиазолопиримидинов |
| RU2178415C2 (ru) * | 1995-12-01 | 2002-01-20 | Американ Цианамид Компани | Усовершенствованный способ получения n-[3-(3-цианопиразоло[1,5-а]пиримидин-7-ил)фенил]-n-этил-ацетамида |
| US7566683B2 (en) | 1996-04-25 | 2009-07-28 | Nissan Chemical Industries, Ltd. | Ethylene derivatives and pesticides containing said derivatives |
| US7037880B2 (en) | 1996-04-25 | 2006-05-02 | Nissan Chemical Industries, Ltd. | Ethylene derivatives and pesticides containing said derivatives |
| US6136809A (en) * | 1996-07-24 | 2000-10-24 | Dupont Pharmaceuticals | Azolo triazines and pyrimidines |
| US6060478A (en) * | 1996-07-24 | 2000-05-09 | Dupont Pharmaceuticals | Azolo triazines and pyrimidines |
| US7094782B1 (en) | 1996-07-24 | 2006-08-22 | Bristol-Myers Squibb Company | Azolo triazines and pyrimidines |
| WO1998003510A1 (en) * | 1996-07-24 | 1998-01-29 | Du Pont Pharmaceuticals Company | Azolo triazines and pyrimidines |
| EP1908764A1 (de) * | 1996-07-24 | 2008-04-09 | Bristol-Myers Squibb Pharma Company | Azolotriazine und Pyrimidine |
| US6124289A (en) * | 1996-07-24 | 2000-09-26 | Dupont Pharmaceuticals Co. | Azolo triazines and pyrimidines |
| US6358950B1 (en) | 1996-07-24 | 2002-03-19 | Bristol-Myers Squibb Pharma Company | Azolo triazines and pyrimidines |
| US7678793B2 (en) | 1996-07-24 | 2010-03-16 | Bristol-Myers Squibb Pharma Company | Azolo triazines and pyrimidines |
| CZ299451B6 (cs) * | 1996-07-24 | 2008-07-30 | Bristol-Myers Squibb Pharma Company | [1,5-a]-Pyrazolo-1,3,5- triaziny jejich použití afarmaceutické kompozice na jejich bázi |
| US6335336B1 (en) | 1997-05-22 | 2002-01-01 | G.D. Searle & Company | 3(5)-Heteroaryl substituted pyrazoles as p38 kinase inhibitors |
| US7153959B2 (en) | 1997-05-22 | 2006-12-26 | Pharmacia Corporation | Substituted pyrazoles as p38 kinase inhibitors |
| US6423713B1 (en) | 1997-05-22 | 2002-07-23 | G. D. Searle & Company | Substituted pyrazoles as p38 kinase inhibitors |
| US5932576A (en) * | 1997-05-22 | 1999-08-03 | G. D. Searle & Company | 3(5)-heteroaryl substituted pyrazoles as p38 kinase inhibitors |
| US6617324B1 (en) | 1997-05-22 | 2003-09-09 | G. D. Searle & Company | Substituted pyrazoles as p38 kinase inhibitors |
| US6852740B2 (en) | 1997-05-22 | 2005-02-08 | G. D. Searle & Co. | Pyrazole derivatives as p38 kinase inhibitors |
| WO1998052937A3 (en) * | 1997-05-22 | 1999-03-11 | Searle & Co | 4-aryl-3(5)-heteroaryl substituted pyrazoles as p38 kinase |
| US6503930B1 (en) | 1997-05-22 | 2003-01-07 | G.D. Searle & Company | Pyrazole derivatives as p38 kinase inhibitors |
| US6514977B1 (en) | 1997-05-22 | 2003-02-04 | G.D. Searle & Company | Substituted pyrazoles as p38 kinase inhibitors |
| US6579873B2 (en) | 1997-05-22 | 2003-06-17 | Pharmacia Corporation | 3 (5)-heteroaryl substituted pyrazoles as p38 kinase inhibitors |
| US6191131B1 (en) | 1997-07-23 | 2001-02-20 | Dupont Pharmaceuticals Company | Azolo triazines and pyrimidines |
| US6313124B1 (en) | 1997-07-23 | 2001-11-06 | Dupont Pharmaceuticals Company | Tetrazine bicyclic compounds |
| US6087496A (en) * | 1998-05-22 | 2000-07-11 | G. D. Searle & Co. | Substituted pyrazoles suitable as p38 kinase inhibitors |
| EP1500657A1 (de) * | 1998-11-20 | 2005-01-26 | G.D. Searle LLC | Substituierte Pyrazole als P38-kinaseinhibitoren |
| US6525059B1 (en) | 1998-11-20 | 2003-02-25 | G. D. Searle & Company | Substituted pyrazoles as p38 kinase inhibitors |
| WO2000031063A1 (en) * | 1998-11-20 | 2000-06-02 | G.D. Searle & Co. | SUBSTITUTED PYRAZOLES AS p38 KINASE INHIBITORS |
| US6562860B1 (en) | 1998-12-23 | 2003-05-13 | G. D. Searle & Co. | Combinations of ileal bile acid transport inhibitors and bile acid sequestering agents for cardiovascular indications |
| US6569905B1 (en) | 1998-12-23 | 2003-05-27 | G.D. Searle, Llc | Combinations of cholesteryl ester transfer protein inhibitors and bile acid sequestering agents for cardiovascular indications |
| US6638969B1 (en) | 1998-12-23 | 2003-10-28 | G.D. Searle, Llc | Combinations of ileal bile acid transport inhibitors and fibric acid derivatives for cardiovascular indications |
| US6458851B1 (en) | 1998-12-23 | 2002-10-01 | G. D. Searle, Llc | Combinations of ileal bile acid transport inhibitors and cholesteryl ester transfer protein inhibitors for cardiovascular indications |
| US6458850B1 (en) | 1998-12-23 | 2002-10-01 | G.D. Searle, Llc | Combinations of cholesteryl ester transfer protein inhibitors and fibric acid derivatives for cardiovascular indications |
| US6489366B1 (en) | 1998-12-23 | 2002-12-03 | G. D. Searle, Llc | Combinations of cholesteryl ester transfer protein inhibitors and nicotinic acid derivatives for cardiovascular indications |
| US6890958B2 (en) | 1998-12-23 | 2005-05-10 | G.D. Searle, Llc | Combinations of cholesteryl ester transfer protein inhibitors and nicotinic acid derivatives for cardiovascular indications |
| US6462091B1 (en) | 1998-12-23 | 2002-10-08 | G.D. Searle & Co. | Combinations of cholesteryl ester transfer protein inhibitors and HMG coA reductase inhibitors for cardiovascular indications |
| US7026317B2 (en) | 1999-04-06 | 2006-04-11 | Bristol-Myers Squibb Pharma Company | Pyrazolotriazines as CRF antagonists |
| US6958341B2 (en) | 1999-04-06 | 2005-10-25 | Bristol-Myers Squibb Pharma Company | Pyrazolopyrimidines as CRF antagonists |
| US6960583B2 (en) | 1999-04-06 | 2005-11-01 | Bristol-Myers Squibb Company | Pyrazolotriazines as CRF antagonists |
| WO2001016138A1 (en) * | 1999-08-27 | 2001-03-08 | Abbott Laboratories | Sulfonylphenylpyrazole compounds useful as cox-2 inhibitors |
| US6472416B1 (en) | 1999-08-27 | 2002-10-29 | Abbott Laboratories | Sulfonylphenylpyrazole compounds useful as COX-2 inhibitors |
| WO2001015525A1 (en) * | 1999-08-31 | 2001-03-08 | Fujisawa Pharmaceutical Co., Ltd. | Organ preservatives |
| US6586434B2 (en) | 2000-03-10 | 2003-07-01 | G.D. Searle, Llc | Method for the preparation of tetrahydrobenzothiepines |
| US6734185B2 (en) | 2000-07-07 | 2004-05-11 | Bristol-Myers Squibb Pharma Company | Pyrrolo[3,4-d]pyrimidines as corticotropin releasing factor (CRF) antagonists |
| US6630476B2 (en) | 2000-07-07 | 2003-10-07 | Bristol-Myers Squibb Pharma Company | Pyrrolo [3,4-d] pyrimidines as corticotropin releasing factor (CRF) antagonists |
| CZ303808B6 (cs) * | 2001-05-24 | 2013-05-09 | Eli Lilly And Company | Nové pyrazolové deriváty jako farmaceutická cinidla |
| WO2002094833A1 (en) * | 2001-05-24 | 2002-11-28 | Eli Lilly And Company | Novel pyrrole derivatives as pharmaceutical agents |
| EA007782B1 (ru) * | 2001-05-24 | 2007-02-27 | Эли Лилли Энд Компани | Новые производные пиррола в качестве фармацевтических средств |
| HRP20030961B1 (en) * | 2001-05-24 | 2012-01-31 | Eli Lilly And Company | Novel pyrrole derivatives as pharmaceutical agents |
| DE10153344A1 (de) * | 2001-10-29 | 2003-05-15 | Gruenenthal Gmbh | Verwendung von substituierten Pyrazolopyrimidinen als Liganden von Nucleosid-Transport-Proteinen und/oder von Purinorezeptoren |
| US6740663B2 (en) | 2001-11-02 | 2004-05-25 | G.D. Searle, Llc | Mono- and di-fluorinated benzothiepine compounds as inhibitors of apical sodium co-dependent bile acid transport (ASBT) and taurocholate uptake |
| US6979686B1 (en) | 2001-12-07 | 2005-12-27 | Pharmacia Corporation | Substituted pyrazoles as p38 kinase inhibitors |
| WO2003053976A1 (en) * | 2001-12-20 | 2003-07-03 | Biovitrum Ab | PIPAZOLO [1,5-a] PYRIMIDINE DERIVATIVES AS MODULATORS OF PPAR |
| US6852753B2 (en) | 2002-01-17 | 2005-02-08 | Pharmacia Corporation | Alkyl/aryl hydroxy or keto thiepine compounds as inhibitors of apical sodium co-dependent bile acid transport (ASBT) and taurocholate uptake |
| US7304068B2 (en) | 2002-05-10 | 2007-12-04 | Smithkline Beecham Corporation | Substituted pyrazolo [1,5-A] pyrimidinyls and pharmaceutical uses therefore |
| WO2003095455A3 (en) * | 2002-05-10 | 2003-12-24 | Smithkline Beecham Corp | Substituted pyrazolopyrimidines |
| WO2004048383A1 (en) * | 2002-11-21 | 2004-06-10 | Eli Lilly And Company | Mixed lineage kinase modulators |
| EA008387B1 (ru) * | 2002-11-22 | 2007-04-27 | Эли Лилли Энд Компани | Хинолинилпирролопиразолы |
| US7265225B2 (en) | 2002-11-22 | 2007-09-04 | Eli Lilly And Company | Quinolinyl-pyrrolopyrazoles |
| US7834029B2 (en) | 2002-11-22 | 2010-11-16 | Eli Lilly And Company | Quinolinyl-pyrrolopyrazoles |
| HRP20050436B1 (hr) * | 2002-11-22 | 2013-11-08 | Eli Lilly And Company | Kinolinil-pirolpirazoli |
| WO2004048382A1 (en) * | 2002-11-22 | 2004-06-10 | Eli Lilly And Company | Quinolinyl-pyrrolopyrazoles |
| US7511065B2 (en) | 2003-11-12 | 2009-03-31 | Eli Lilly And Company | Mixed lineage kinase modulators |
| WO2009076440A3 (en) * | 2007-12-12 | 2009-09-24 | E.I. Du Pont De Nemours And Company | Fungicidal bicyclic pyrazoles |
| US8288375B2 (en) | 2007-12-12 | 2012-10-16 | E.I. Du Pont De Nemours And Company | Fungicidal bicyclic pyrazoles |
| US8969376B2 (en) | 2010-02-26 | 2015-03-03 | Mitsubishi Tanabe Pharma Corporation | Pyrazolopyrimidine compounds and their use as PDE10 inhibitors |
| WO2011105628A1 (en) * | 2010-02-26 | 2011-09-01 | Mitsubishi Tanabe Pharma Corporation | Pyrazolopyrimidine compounds and their use as pde10 inhibitors |
| EP2402345A1 (de) * | 2010-06-29 | 2012-01-04 | Basf Se | Pyrazole kondensierte bizyclische Verbindungen |
| EP2402339A1 (de) | 2010-06-29 | 2012-01-04 | Basf Se | Pyrazolopyridin-Verbindungen |
| EP2402344A1 (de) * | 2010-06-29 | 2012-01-04 | Basf Se | Pyrazolkondensierte bicyclische Verbindungen |
| WO2013050437A1 (en) | 2011-10-06 | 2013-04-11 | Bayer Intellectual Property Gmbh | Heterocyclylpyri (mi) dinylpyrazole as fungicidals |
| WO2015035062A1 (en) * | 2013-09-05 | 2015-03-12 | Genentech, Inc. | Antiproliferative compounds |
| US9505767B2 (en) | 2013-09-05 | 2016-11-29 | Genentech, Inc. | Pyrazolo[1,5-A]pyrimidin-7(4H)-onehistone demethylase inhibitors |
| CN105611933B (zh) * | 2013-09-05 | 2019-01-25 | 基因泰克公司 | 抗增生性化合物 |
| US12503439B2 (en) | 2022-04-22 | 2025-12-23 | Vertex Pharmaceuticals Incorporated | Heteroaryl compounds for the treatment of pain |
Also Published As
| Publication number | Publication date |
|---|---|
| US5356897A (en) | 1994-10-18 |
| AU2280592A (en) | 1993-03-11 |
| US5624931A (en) | 1997-04-29 |
| JPH07252256A (ja) | 1995-10-03 |
| HU9202877D0 (en) | 1992-11-30 |
| US5478827A (en) | 1995-12-26 |
| JPH0788386B2 (ja) | 1995-09-27 |
| CN1070404A (zh) | 1993-03-31 |
| MX9205145A (es) | 1993-04-01 |
| JPH06287188A (ja) | 1994-10-11 |
| HUT65204A (en) | 1994-05-02 |
| IL102946A0 (en) | 1993-01-31 |
| CA2077732A1 (en) | 1993-03-10 |
| EP0531901A3 (de) | 1993-05-05 |
| TW257763B (de) | 1995-09-21 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US5356897A (en) | 3-(heteroaryl)-pyrazololi[1,5-a]pyrimidines | |
| EP0686156B1 (de) | Pyrazolotriazine mit interleukin-1 und tumor necrosis faktor inhibitor wirkung | |
| AU656576B2 (en) | Quinoline derivatives | |
| WO1992012154A1 (en) | Imidazotriazine derivatives | |
| EP0770079B1 (de) | Heterobizyklische derivate | |
| AU694157B2 (en) | Pyrazolopyridine adenosine antagonists | |
| ES2319797T3 (es) | Derivados de pirazolopiridina. | |
| WO1992002513A1 (en) | Heterocyclic compounds | |
| EP0874845B1 (de) | Pyrido (2,3-b) pyrazinderivate | |
| AU664068B2 (en) | Heterotricyclic derivatives, process for their preparation and pharmaceutical compositions containing them | |
| HUT71352A (en) | Heterocyclic derivatives | |
| JPH06239864A (ja) | 新規複素環誘導体 | |
| HK1004483B (en) | Heterobicyclic derivatives |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PUAI | Public reference made under article 153(3) epc to a published international application that has entered the european phase |
Free format text: ORIGINAL CODE: 0009012 |
|
| PUAL | Search report despatched |
Free format text: ORIGINAL CODE: 0009013 |
|
| AK | Designated contracting states |
Kind code of ref document: A2 Designated state(s): AT BE CH DE DK ES FR GB GR IE IT LI LU NL PT SE |
|
| AK | Designated contracting states |
Kind code of ref document: A3 Designated state(s): AT BE CH DE DK ES FR GB GR IE IT LI LU NL PT SE |
|
| 17P | Request for examination filed |
Effective date: 19931026 |
|
| 17Q | First examination report despatched |
Effective date: 19970203 |
|
| 18D | Application deemed to be withdrawn |
Effective date: 19981223 |